CHEST 2021: Study shows vaping raises the odds of developing asthma and COPD, especially in older adults, women, and Hispanic persons.
In patients with severe asthma dependent on OCS, dupilumab reduced OCS dose and improved the odds of no longer requiring OCS, suggests research presented at CHEST 2021.
CHEST 2021: Patients with severe asthma who received tezepelumab compared with placebo demonstrated rapid improvement in morning and evening peak expiratory flow.
COVID-19 case increases in the past 7 days range from 100% to 3.16% among the 10 states with the most significant rises. Is your state among these?
A variety of exposures in the work environment can cause asthma in some employees, according to new research presented at ERS Virtual International Congress 2021.
The albuterol/budesonide combination significantly reduced the risk of severe exacerbations and improved lung function in mild-to-moderate asthma.
A new study found several risk factors associated with severe adult-onset asthma, including smoking, NSAID-exacerbated respiratory disease, and sibling count.
A new study found public health measures designed to curb COVID-19 transmissions may have fostered a significant side benefit: reduced COPD hospital admissions.
ATS 2021: In a subgroup of oral corticosteroid-dependent patients with severe asthma from the newly released NAVIGATOR study, tezepelumab reduced exacerbations and improved lung function.
ATS.2021. Study authors categorized asthma patients using age at onset, T2 biomarkers, and IL-6 levels, creating 12 phenotypes for additional study.